November 2026

WyoBlue Advantage is informing providers of upcoming changes for medical benefit drugs

Changes to preferred drug designations for Bevacizumab, Filgrastim, and Pegfilgrastim products starting January 1, 2027

Prior authorization requirements currently apply to these products. Review the posted Part B Drug List to confirm the preferred product(s) and applicable effective dates.

Changes to Step Therapy requirements effective January 1, 2027

- Q5154 Omlyclo (Omalizumab-igec) requires trial and failure of Xolair

Drugs Newly Requiring Prior Authorization Effective January 1, 2027

- J9264 Abraxane (Paclitaxel protein-bound particles)
- J1454 Akynzeo (Netupitant/ palonosetron)
- J9305 Alimta (Pemetrexed)
- Q5169 Armlupeg (Pegfilgrastim-unne)
- J9184 Avgemsi (Gemcitabine)
- J9292 Axtle (Pemetrexed)
- J9023 Bavencio (Avelumab)
- J9174 Beizray (Docetaxel)
- J9382 Bizengri (Zenocutuzumab-zbco)
- J9053 Blenrep (Belantamab mafodontin-blmf)
- J9054 Boruzu (Bortezomib)
- J0185 Cinvanti (Aprepitant)
- J9286 Columvi (Glofitamab-gxbm)
- J1448 Cosela (Trilaciclib)
- J9308 Cyramza (Ramucirumab)
- J9348 Danyelza (Naxitamab-gqgk)
- J9011 Datroway (Datopotamab deruxtecan-dlnk)
- J3590 Degevma (Denosumab-adet)
- J9172 Docivyx (Docetaxel)
- J9063 Elahere (Mirvetuximab soravtansine)
- J1323 Elrexfio (Elranatamab-bcmm)
- J9269 Elzonris (Tagraxofusp-erzs)
- J9326 Emrelis (Telisotuzumab vedotin-tllv)
- J9358 Enhertu (Fam-trastuzumab-nxki)
- J9055 Erbitux (Cetuximab)

- J1428 Exondys 51 (Eteplirsen)
- J1434 Focinvez (Fosaprepitant)
- J9072 Frindovyx (Cyclophosphamide)
- Q5108 Fulphila (Pegfilgrastim-jmdb)
- J9331 Fyarro (Sirolimus albumin-bound)
- J1460 GamaSTAN, GamaSTAN S/D (Immune globulin (human), IM)
- J1560 GamaSTAN, GamaSTAN S/D (Immune globulin (human), IM (Over 10 mL))
- J9210 Gamifant (Emapalumab-lzsg)
- J9301 Gazyva (Obinutuzumab)
- J9314 Generic (Pemetrexed)
- J9294, J9296, J9297 Generic (various brands) (Pemetrexed)
- J9322, J9323 Generic (various brands) (Pemetrexed)
- J3590 Genglycos (Pariglasgene brecaparvovec-opnr)
- J9356 Herceptin Hylecta (Trastuzumab and hyaluronidase-oysk)
- J0638 Ilaris (Canakinumab)
- J9347 Imjudo (Tremelimumab-actl)
- J9183 Inlexzo (Gemcitabine intravesical system)
- J9281 Jelmyto (Mitomycin)
- J9272 Jemperli (Dostarlimab-gxly)
- Q5160 Jobevne (Bevacizumab-nwgd)
- J9354 Kadcyla (Ado-trastuzumab emtansine)
- J9277 Keytruda Qlex (Pembrolizumab and berahyaluronidase alfa-pmph)
- J0642 Khapzory (Levoleucovorin)
- J9274 Kimmtrak (Tebentafusp-tebn)
- J9278 Kyxata (Carboplatin)
- J3263 Loqtorzi (Toripalimab-tpzi)
- J3590 Lucamzi (Ranibizumab-blrz)
- J9350 Lunsumio IV (Mosunetuzumab-axgb)
- J9350 Lunsumio VELO (Mosunetuzumab-axgb)
- J9601 Lynozyfic (Linvoseltamab-gcpt)
- J9353 Margenza (Margetuximab-cmkb)
- J9349 Monjuvi (Tafasitamab-cxix)
- Q5107 Mvasi (Bevacizumab-awwb)
- J2506 Neulasta® Neulasta® Onpro® (Pegfilgrastim)
- Q5110 Nivestym (Filgrastim-aafi)
- Q5122 Nyvepria (Pegfilgrastim-apgf)
- J3406 Omisirge (Omidubicel-onlv)

- J9205 Onivyde (Irinotecan liposome)
- Q5112 Ontruzant (Trastuzumab-dttb)
- J9298 Opdualag (Nivolumab and relatlimab-rmbw)
- J9177 Padcev (Enfortumab vedotin-ejfv)
- J9324 Pemrydi RTU (Pemetrexed)
- J9306 Perjeta (Pertuzumab)
- J9316 Phesgo (Pertuzumab/trastuzum ab/hyaluronidase-zzxf)
- J9309 Polivy (Polatuzumab)
- J9204 Poteligeo (Mogamulizumab-kpkc)
- J2820 Prokine, Leukine (Sargramostim)
- J9061 Rybrevant (Amivantamab-vmjw)
- J9062 Rybrevant Faspro (Amivantamab and hyaluronidase-lpuj)
- J2998 Ryplazim (Plasminogen, human-tvmh)
- J7352 Scenesse (Afamelanotide)
- J1627 Sustol (Granisetron)
- J2779 Susvimo (Ranibizumab injection, for ocular implant)
- J3055 Talvey (Talquetamab-tgvs)
- J9329 Tevimbra (Tislelizumab-jsgr)
- J9273 Tivdak (Tisotumab vedotin-tftv)
- Q5116 Trazimera (Trastuzumab-qyyp)
- J9317 Trodelvy (Sacituzumab govitecan-hziy)
- J9275 Unloxcyt (Cosibelimab-ipdl)
- J9303 Vectibix (Panitumumab)
- Q4074 Ventavis (Iloprost)
- J1427 Viltepso (Viltolarsen)
- J9056 Vivimusta (Bendamustine)
- J3590 Voceryq (Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd)
- J1326 Vyloy (Zolbetuximab-clzb)
- J1429 Vyondys 53 (Golodirsen)
- J0218 Xenpozyme (Olipudase alfa-rpcp)
- Q5101 Zarxio (Filgrastim-sndz)
- J9276 Ziihera (Zanidatamab-hrii)
- Q5118 Zirabev (Bevacizumab-bvzr)
- J9282 Zusduri (Mitomycin)
- J9359 Zynlonta (Loncastuximab tesirine-lpyl)
- J3393 Zynteglo (Betibeglogene autotemcel)
- J9345 Zynyz (Retifanlimab-dlwr)

Prior Authorization Submission Methods

Prior approval must be submitted through one of the following methods:

- Electronically: Use the Symphony Prior Authorization Portal, available within the Availity Essentials portal.
- Phone call: (844) 965-5080
- Paper form/Fax: Download the form from the WyoBlue Advantage website and fax it to (877) 369-3365.